Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie

(+)-BORNEOL [464-43-7]

Drucken

Katalog-Nummer NB-64-30136-1mL

Size : 1mLx10mM(inDMSO)

Contact local distributor :

Telefonnummer : +1 850 650 7790

Weitere Informationen anfordern

Contact local distributor :

Telefonnummer : +1 850 650 7790

Remove All

(+)-BORNEOL

(Synonyms: d-Borneol) Copy Product Info

Synonyms: d-Borneol

Catalog No. T5734 Copy Product Info

Purity: 99.6%

(+)-BORNEOL (d-Borneol) is a natural bicyclic monoterpene used for analgesia and anesthesia in traditional Chinese medicine; enhances GABA receptor activity with an EC50 of 248 μM.

Cas No. 464-43-7

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.6%

Color:White

Product Introduction

Bioactivity

Description	(+)-BORNEOL (d-Borneol) is a natural bicyclic monoterpene used for analgesia and anesthesia in traditional Chinese medicine; enhances GABA receptor activity with an EC50 of 248 μM.
Targets & IC50	GABA:248 μM(EC50)
In vitro	Aβ-induced cell cytotoxicity was inhibited by 100 μM of (-) and (+) borneol treatment. Treatment of borneol significantly decreased ROS generation (P < 0.01). The expression of HO-1 and nuclear translocation of Nrf2 were increased by Aβ treatment. This nuclear translocation of Nrf2 was further increased by administration of borneol. Compared with the Aβ treated group, the (+) borneol treated group significantly increased Bcl-2 expression with decreased expression of Bax[1].
In vivo	(+)-borneol (1.0 mg/kg) significantly ameliorated infarct size and neurological scoresvia reducing the expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-alpha (TNF-α) in a dose dependent manner. Notably, (+)-borneol showed long-term effects on the improvement of sensorimotor functions in the photothrombotic model of stroke, which decreased the number of foot faults in the grid-walking task and forelimb asymmetry scores in the cylinder task, at least in part through reducing loss of dendritic spines in the length, brunch number and density. Suggest that (+)-borneol could serve as a therapeutic target for ischemic stroke[2].
Synonyms	d-Borneol
Cell Research	Oxidative stress was induced by administering 50 μM Aβ into SH-SY5Y cells. Neuroprotective effect of commercially available borneol was examined by determining cell viability with the MTT assay. Intracellular reactive oxygen species (ROS) generation was measured using a fluorometer with further examination of heme oxygenase-1 (HO-1) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) expression. Apoptosis was examined by measuring the ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax)[1].
Animal Research	To mimic a typical human stroke, which does not undergo reperfusion, used a permanent MCAO in this study. For investigating the role of (+)-borneol in permanent cerebral ischemia, 45 male Sprague-Dawley rats were randomly divided into the sham group, the vehicle-treated group and the (+)-borneol-treated groups (1.0 mg/kg), with 15 rats in each group. The terminal half-life (t1/2) of borneol was 2 h following cerebral ischemia-reperfusion. We subjected the rats to pMCAO and administered drugs by tail intravenous injection 2 hours and 5 hours after pMCAO, respectively. The sham group and the vehicle-treated group were injected with vehicle administration. Neurologic scores were assessed at 48 hours after reperfusion[2].

Chemical Properties

Molecular Weight	154.25
Formula	C₁₀H₁₈O
Cas No.	464-43-7
Smiles	CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2
Relative Density.	0.992g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 247.5 mg/mL (1604.54 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (25.93 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	6.4830 mL	32.4149 mL	64.8298 mL	324.1491 mL
5 mM	1.2966 mL	6.4830 mL	12.9660 mL	64.8298 mL
10 mM	0.6483 mL	3.2415 mL	6.4830 mL	32.4149 mL
20 mM	0.3241 mL	1.6207 mL	3.2415 mL	16.2075 mL
50 mM	0.1297 mL	0.6483 mL	1.2966 mL	6.4830 mL
100 mM	0.0648 mL	0.3241 mL	0.6483 mL	3.2415 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

GABAReceptorGABA ReceptorGABABORNEOL(+)BORNEOL(+) BORNEOL

Related Tags: (+)-BORNEOL chemical structure | (+)-BORNEOL in vivo | (+)-BORNEOL in vitro | (+)-BORNEOL formula | (+)-BORNEOL molecular weight